Search

Objective: Stroke and traumatic brain injury (TBI) are among the leading causes of disability. Even after engaging in rehabilitation, nearly half of patients with severe TBI requiring hospitalization are left with major disability. Despite decades of investigation, pharmacologic treatment of brain injury is still a field in its infancy. Recent clinical trials have begun into the use of psychedelic therapeutics for treatment of brain injury. This brief review aims to summarize the current state of the science's relevance to neurorehabilitation, and may act as a resource for those seeking to understand the precedence for these ongoing clinical trials.Methods: Narrative mini-review of studies published related to psychedelic therapeutics and brain injury.Results: Recent in vitro, in vivo, and case report studies suggest psychedelic pharmacotherapies may influence the future of brain injury treatment through modulation of neuroinflammation, hippocampal neurogenesis, neuroplasticity, and brain complexity.Conclusions: Historical data on the safety of some of these substances could serve in effect as phase 0 and phase I studies. Further phase II trials will illuminate how these drugs may treat brain injury, particularly TBI and reperfusion injury from stroke.

Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular cannabinoid-based medicines (CBM). Clinicians, meanwhile, feel understandably perplexed by the discrepancy between the available evidence and the rapid interest in which patients and their families have demonstrated for CBM. There is an urgent need to address the many challenges that are delaying the appropriate integration of CBM into clinical practice, notwithstanding the obvious need for a solid general knowledge of pharmacology, mechanism of action and available clinical evidence supporting its use. The authors will address these challenges and provide practical recommendations regarding patient assessment for the use of CBM. The authors will also make suggestions regarding patient expectations in order to define clear objectives, review the necessary precautions prior to initiating treatment, aid in selecting the appropriate strain and route of administration as well as establishing proper titration and monitoring protocols. The authors will also discuss the lesser known but potentially therapeutic psychoactive effects of cannabis. As this class of therapeutic agents are likely to play a major role in palliative medicine in the near future, clinicians would benefit from familiarizing themselves with CBM and we can expect that patients and their caregivers will appreciate receiving support in their search for safe and effective therapeutic alternatives.

Cannabis (marijuana) has been used for medicinal purposes for millennia, said to be first noted by the Chinese in c. 2737 BCE. Medicinal cannabis arrived in the United States much later, burdened with a remarkably checkered, yet colorful, history. Despite early robust use, after the advent of opioids and aspirin, medicinal cannabis use faded. Cannabis was criminalized in the United States in 1937, against the advice of the American Medical Association submitted on record to Congress. The past few decades have seen renewed interest in medicinal cannabis, with the National Institutes of Health, the Institute of Medicine, and the American College of Physicians, all issuing statements of support for further research and development. The recently discovered endocannabinoid system has greatly increased our understanding of the actions of exogenous cannabis. Endocannabinoids appear to control pain, muscle tone, mood state, appetite, and inflammation, among other effects. Cannabis contains more than 100 different cannabinoids and has the capacity for analgesia through neuromodulation in ascending and descending pain pathways, neuroprotection, and anti-inflammatory mechanisms. This article reviews the current and emerging research on the physiological mechanisms of cannabinoids and their applications in managing chronic pain, muscle spasticity, cachexia, and other debilitating problems.

Objectives: This study was conducted to better understand the characteristics of chronic pain patients seeking treatment with medicinal cannabis (MC). Design: Retrospective chart reviews of 139 patients (87 males, median age 47 years; 52 females, median age 48 years); all were legally qualified for MC use in Washington State. Setting: Regional pain clinic staffed by university faculty. Participants: Inclusion criteria: age 18 years and older; having legally accessed MC treatment, with valid documentation in their medical records. All data were de-identified. Main Outcome Measures: Records were scored for multiple indicators, including time since initial MC authorization, qualifying condition(s), McGill Pain score, functional status, use of other analgesic modalities, including opioids, and patterns of use over time. Results: Of 139 patients, 15 (11 percent) had prior authorizations for MC before seeking care in this clinic. The sample contained 236.4 patientyears of authorized MC use. Time of authorized use ranged from 11 days to 8.31 years (median of 1.12 years). Most patients were male (63 percent) yet female patients averaged 0.18 years longer authorized use. There were no other gender-specific trends or factors. Most patients (n = 123, 88 percent) had more than one pain syndrome present. Myofascial pain syndrome was the most common diagnosis (n = 114, 82 percent), followed by neuropathic pain (n = 89, 64 percent), discogenic back pain (n = 72, 51.7 percent), and osteoarthritis (n = 37, 26.6 percent). Other diagnoses included diabetic neuropathy, central pain syndrome, phantom pain, spinal cord injury, fibromyalgia, rheumatoid arthritis, HIV neuropathy, visceral pain, and malignant pain. In 51 (37 percent) patients, there were documented instances of major hurdles related to accessing MC, including prior physicians unwilling to authorize use, legal problems related to MC use, and difficulties in finding an affordable and consistent supply of MC. Conclusions: Data indicate that males and females access MC at approximately the same rate, with similar median authorization times. Although the majority of patient records documented significant symptom alleviation with MC, major treatment access and delivery barriers remain.

Objective:With the ongoing expansion of palliative care services throughout the United States, meeting the needs of socioeconomically marginalized populations, as in all domains of healthcare, continues to be a challenge. Our specific aim here was to help meet some of these needs through expanding delivery of pain and palliative care services by establishing a new clinic for underserved patients and collecting descriptive data about its operation.Method:In November of 2014, the National Institutes of Health Clinical Center's Pain and Palliative Care Service (PPCS) launched a bimonthly offsite pain and palliative care outpatient clinic in collaboration with Mobile Medical Care Inc. (MobileMed), a private not-for-profit primary care provider in Montgomery County, Maryland, serving underserved area residents since 1968. Staffed by NIH hospice and palliative medicine clinical fellows and faculty, the clinic provides specialty pain and palliative care consultation services to patients referred by their primary care healthcare providers. A patient log was maintained, charts reviewed, and referring providers surveyed on their satisfaction with the service.Results:The clinic had 27 patient encounters with 10 patients (6 males, 4 females, aged 23–67) during its first 7 months of operation. The reason for referral for all but one patient was chronic pain of multiple etiologies. Patients had numerous psychosocial stressors and comorbidities. All primary care providers who returned surveys (n = 4) rated their level of satisfaction with the consultation service as “very satisfied” or “extremely satisfied.”Significance of Results:This brief descriptive report outlines the steps taken and logistical issues addressed to launch and continue the clinic, the characteristics of patients treated, and the results of quality-improvement projects. Lessons learned are highlighted and future directions suggested for the clinic and others that may come along like it.

Objective: This study aimed to investigate the predictive value of circumferential iliofemoral calcifications and current manufacturer recommendations, which are not evidence-based, in transfemoral (TF) transcatheter aortic valve implantation (TAVI) Methods: A patient cohort with a broad range of iliofemoral anatomies undergoing TF TAVI (n=132) were retrospectively divided as “suitable” (n=76, 58%) and “unsuitable” (n=56, 42%) candidates according to current recommendations. Iliofemoral angiography and reconstructed mul- tislice CT (MSCT) images were used for access screening in the majority of patients. Results: Vessel properties were significantly worse in the “unsuitable group.” The sheath-to-iliofemoral artery ratio (SIFAR) and calcium score were 1.35±0.2 and 1.7±0.8 in the unsuitable group, compared to 1.0±0.12 (p

Here I take up calls to engage in developing an “ethnobiology of us,” in which Western biota-cultural relations are centered. When Western-influenced scholars study extinct and extant cultures of cannabis cultivation, trade, and consumption in celebratory, reverential, or mundane contexts, it is crucial for appropriate self-reflective positionality to appreciate the power, persistence, and remarkable idiosyncrasy of the western socioecological worldview of cannabis. In humancannabis relations, I argue this is essential, as the Western worldview carries profound hegemonic weight, influencing preconceptions of scholars and global societies. A prevailing Western notion is that close contact with cannabis is socially legitimate only for a privileged few and otherwise harshly criminalized and stigmatized. Constructed scarcity and inequitable accessibility of this traditional and widely cultivated species and its products are ubiquitous, including near-total invisibility of wild and cultivated plots.Drawing upon my own memories and reflections navigating multiple cannabis-related cultural frames, spanning from disgust to fear and curiosity to reverence, I will chronicle the cannabis and the various cultural frames in which it was embedded, which I have passively or actively encountered throughout my life, including in my training and practice as a geographer and medical doctor. The thematic arc has been shifting from alienating to allying with cannabis, yet, at the same time, being ever-vigilant of the official marginality of that alliance and related structural violence. To adapt to that social marginalization, I have come to accept various logics that connect cannabis with the body, stretching from spiritual and cosmological, cultural-traditional, and pharmacological-biochemical.

Patients using medical cannabis in the United States inhabit a con- flicting medicolegal space. This study presents data from a dispensary-based survey of patients using medical cannabis in the state of Washington regarding cannabis-specific health behaviors, levels of psychological distress, stress regard- ing marijuana criminality, past experiences with drug law enforcement, and coping behaviors. Thirty-seven subjects were enrolled in this study, and all but three completed survey materials. The median index of psychological distress, as measured by the Behavioral Symptom Inventory, was nearly 2.5 times higher than that found in a general population sample but one third less than that found in an outpatient sample. The subjects reported a moderate amount of stress related to the criminality of marijuana, with 76% reporting previous exposure to 119 separate drug law enforcement tactics in total. The subjects reported a wide range of coping methods, and their responses to a modified standardized survey showed the confounding influence of legality in assessing substance- related disorders.

This article attempts to cover pragmatic clinical considerations involved in the use of cannabinergic medicines in pain practice, including geographical and historical considerations, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, indications, and contraindications. Topics include molecular considerations such as the 10-fold greater abundance of cannabinoid type 1 receptors compared to µ-opioid receptors in the central nervous system and anatomic distributions of cannabinoid receptors in pain circuits.The article uses a narrative review methodology drawing from authoritative textbooks and journals of cannabinoid medicine, Food and Drug Administration-approved cannabinoid drug labels, and current and historical pain medicine literature to address core clinical considerations. To survey the current evidence base for pain management with cannabinergic medicines, a targeted PubMed search was performed to survey the percentage of positive and negative published randomized-controlled trial (RCT) results with this class of pain medicines, using appropriate search limit parameters and the keyword search string "cannabinoid OR cannabis-based AND pain."Of the 56 hits generated, 38 published RCTs met the survey criteria. Of these, 71% (27) concluded that cannabinoids had empirically demonstrable and statistically significant pain-relieving effects, whereas 29% (11) did not.Cannabis and other cannabinergic medicines' efficacies for relieving pain have been studied in RCTs, most of which have demonstrated a beneficial effect for this indication, although most trials are short-term. Adverse effects are generally nonserious and well tolerated. Incorporating cannabinergic medicine topics into pain medicine education seems warranted and continuing clinical research and empiric treatment trials are appropriate.

Integrating cim into oncologic palliative care promises to improve overall health-related quality of life, to provide further relief from distressing symptoms and spiritual suffering, and to bring hope to patients and families facing terminal illness. O’Shaughnessy offers the following somber reflection7: It seems evident that at least one advantage was gained from the use of the remedy—the awful malady was stripped of its horrors; if not less fatal than before, it was reduced to less than the scale of suffering which precedes death from most ordinary diseases.... Next to cure, the physician will perhaps esteem the means which enable him “to strew the path to the tomb with flowers,” and to divest of its specific terrors the most dreadful malady to which mankind is exposed.

Objectives: To characterize health-related quality of life (HRQoL) in medical cannabis patients. Methods: Short Form 36 (SF-36) Physical Health Component Score and Mental Health Component Score (MCS) surveys as well has CDC (Centers for Disease Control) HRQoL-14 surveys were completed by 37 qualified patients. Results: Mean SF-36 PCS and MCS, normalized at 50, were 37.4 and 44.2, respectively. Eighty percent of participants reported activity/functional limitations secondary to impairments or health problems. Patients reported using medical cannabis to treat a wide array of symptoms across multiple body systems with relief ratings consistently in the 7-10/10 range. Conclusion: The HRQoL results in this sample of medical cannabis-using patients are comparable with published norms in other chronically ill populations. Data presented provide insight into medical cannabis-using patients’ self-rated health, HRQoL, disease incidences, and cannabis-related symptom relief.

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I (dangerous, without medical uses). Dronabinol, a Schedule III prescription drug, is 100% tetrahydrocannabinol (THC), the most psychoactive ingredient in cannabis. Cannabis contains 20% THC or less but has other therapeutic cannabinoids, all working together to produce therapeutic effects. As palliative medicine grows, so does the need to reclassify cannabis. This article provides an evidence-based overview and comparison of cannabis and opioids. Using this foundation, an argument is made for reclassifying cannabis in the context of improving palliative care and reducing opioid-related morbidity.

Significant advances have increased our understanding of the molecular mechanisms of amyotrophic lateral sclerosis (ALS), yet this has not translated into any greatly effective therapies. It appears that a number of abnormal physiological processes occur simultaneously in this devastating disease. Ideally, a multidrug regimen, including glutamate antagonists, antioxidants, a centrally acting anti-inflammatory agent, microglial cell modulators (including tumor necrosis factor alpha [TNF-α] inhibitors), an antiapoptotic agent, 1 or more neurotrophic growth factors, and a mitochondrial function-enhancing agent would be required to comprehensively address the known pathophysiology of ALS. Remarkably, cannabis appears to have activity in all of those areas. Preclinical data indicate that cannabis has powerful antioxidative, anti-inflammatory, and neuroprotective effects. In the G93A-SOD1 ALS mouse, this has translated to prolonged neuronal cell survival, delayed onset, and slower progression of the disease. Cannabis also has properties applicable to symptom management of ALS, including analgesia, muscle relaxation, bronchodilation, saliva reduction, appetite stimulation, and sleep induction. With respect to the treatment of ALS, from both a disease modifying and symptom management viewpoint, clinical trials with cannabis are the next logical step. Based on the currently available scientific data, it is reasonable to think that cannabis might significantly slow the progression of ALS, potentially extending life expectancy and substantially reducing the overall burden of the disease.

M.J. is a 54-year-old woman with diffuse low back and bilateral leg pain. She has had 4 spinal surgeries over the past 12 years for her pain, including 2 laminectomies at L4-L5 and L5-S1, a fusion from L4-L5 to the sacrum, and a subsequent revision from L3 to the sacrum. The first surgery provided her 4 years of relief, but all other surgeries resulted in no measurable relief. Various interventional treatments have failed to help, including a spinal cord stimulator trial. She has no focal weakness on lower limb examination but has some subjective numbness in her lower extremities bilaterally and is areflexic in the Achilles tendon bilaterally. She sees a pain psychologist weekly for sessions that include pain coping skills and biofeedback. She denies any depression and scores well on standardized depression inventories. The apparent lack of depression may be due to the psychoaffective effects of opioids; she currently takes scheduled sustained release oxycodone 40 mg every 12 hours, with occasional oxycodone for breakthrough pain control. However, she believes that thesemedications only partially control her pain. She has had routine urine drug screens that show compliance with the treatment regimen. She has heard of people taking medical marijuana for pain control and wonders if that will be a viable option for her instead of escalating the dose of opioids. Sunil K. Aggarwal, MD, PhD, and Gregory Carter, MD, MS, will argue that medical marijuana is an appropriate treatment for this patient, and Sanjog Pangarkar, MD, Mark Miedema, MD, and Bianca Tribuzio, DO, will argue that medical marijuana is not a viable option for this patient.

A series of novel labeled phosphoramidites and CPG supports 1a-f with a new non-nucleosidic backbone based upon cyclohexyl-4-amino-1,1-dimethanol have been synthesized. These reagents have been used to label oligonucleotides with biotin and fluorescein at the 5′-, the 3′-, and internal positions.

"Paradoxical" Low flow, low gradient severe aortic valve stenosis (PLF-LG-AS) is characterized by reduced stroke volume despite preserved EF. If managed conservatively this entity of AS is associated with poor prognosis. Our observational single center study aimed to investigate the outcome of these

The medicinal use of cannabis is a growing phenomenon in the U.S. predicated on the success of overcoming specific spatial challenges and establishing particular human-environment relationships. This article takes a medical geographic "snapshot" of an urban site in Washington State where qualifying chronically ill and debilitated patients are delivered locally produced botanical cannabis for medical use. Using interview, survey, and observation, this medical geographic research project collected information on the social space of the particular delivery site and tracked the production cost, reach, and health value of a 32-ounce batch of strain-specific medical cannabis named "Plum" dispensed over a four-day period. A convenience sample of 37 qualifying patients delivered this batch of cannabis botanical medicine was recruited and prospectively studied with survey instruments. Results provide insight into patients' self-rated health, human-plant relationships, and travel-to-clinic distances. An overall systematic geographic understanding of the medical cannabis delivery system gives a grounded understanding of the lengths that patients and care providers go, despite multiple hurdles, to receive and deliver treatment with botanical cannabis that relieves diverse symptoms and improves health-related quality-of-life.

To find clearheaded scientific perspective on cannabis use through the prevailing thick smokescreen requires recognizing just what sort of smoke obscures our better understanding. In the United States, in large part, the smokescreen is made up of culture war-charged political rhetoric and obstructionism from those in positions of authority setting up a prejudicial ideological framing for cannabis use. National leaders throughout the twentieth century have taken opportunities afforded by high office or its pursuit to publicly opine on the dangers of cannabis, such as when then-Presidential candidate Ronald Reagan famously stated in 1980 that “leading medical researchers are coming to the conclusion that marijuana, pot, grass, whatever you want to call it, is probably the most dangerous drug in the United States and we haven't begun to find out all of the ill-effects. But they are permanent ill-effects. The loss of memory, for example Grass (1999).” Not only is such rhetoric overly simplistic, it also obscures and distorts pre-existing facts. In this particular case, Reagan's statement obscures the fact that the American Medical Association testified in 1937 on record to Congress that, after nearly 100 years of professional experience in Western medical practice with over 2000 prescribable marketed cannabis preparations (Antique Cannabis Museum, 2012), practitioners found that cannabis had an irreplaceable therapeutic role as an aid in the remembering of old and long-forgotten memories in psychotherapy patients (U.S. Congress, 1937). When in office, Reagan's first drug czar, Carlton Turner, blamed cannabis use for young people's involvement in “anti-military, anti-nuclear power, anti-big business, anti-authority demonstrations” (Schlosser, 1997), all dissenting positions toward government initiatives. Such clear scapegoating rhetoric has roots in the government's racialized Reefer Madness campaign of the 1930s which linked cannabis use in Blacks, Latinos, jazz musicians, and juvenile delinquents to racial miscegenation and homicidal mania (Helmer, 1975).

The goal of this paper is to both understand and depathologize clinically significant mental distress related to criminalized contact with psychoactive biotic substances by employing a framework known as critical political ecology of health and disease from the subdiscipline of medical geography. The political ecology of disease framework joins disease ecology with the power-calculus of political economy and calls for situating health-related phenomena in their broad social and economic context, demonstrating how large-scale global processes are at work at the local level, and giving due attention to historical analysis in understanding the relevant human-environment relations. Critical approaches to the political ecology of health and disease have the potential to incorporate ever-broadening social, political, economic, and cultural factors to challenge traditional causes, definitions, and sociomedical understandings of disease. Inspired by the patient-centered medical diagnosis critiques in medical geography, this paper will use a critical political ecology of disease approach to challenge certain prevailing sociomedical interpretations of disease, or more specifically, mental disorder, found in the field of substance abuse diagnostics and the related American punitive public policy regimes of substance abuse prevention and control, with regards to the use of biotic substances. It will do this by first critically interrogating the concept of "substances" and grounding them in an ecological context, reviewing the history of both the development of modern substance control laws and modern substance abuse diagnostics, and understanding the biogeographic dimensions of such approaches. It closes with proposing a non-criminalizing public health approach for regulating human close contact with psychoactive substances using the example of cannabis use.

A series of novel labeled phosphoramidites and CPG supports 1a-f with a new non-nucleosidic backbone based upon cyclohexyl-4-amino-1,1-dimethanol have been synthesized. These reagents have been used to label oligonucleotides with biotin and fluorescein at the 5′-, the 3′-, and internal positions.

A series of prodrugs of zidovudine (AZT) has been synthesized in an effort to enhance the uptake of the prodrugs by the HIV-1 infected cells and to increase the plasma half-life of AZT. The 5'-OH function of AZT was esterified with various acids in the presence of DCC and 4-(dimethylamino)pyridine (DMAP). The prodrug moieties included (a) morpholine and N-phenylpiperazine-1-acetic acid, (b) 1,4-dihydro-1-methyl-3-nicotinic acid, (c) retinoic acid, and (d) certain amino acids. The anti-HIV-1 activity of the esters was determined in peripheral blood lymphocytes. The IC50 for AZT in this system was 0.12 microM whereas for prodrugs it ranged from 0.05 to 0.2 microM. The prodrugs were generally less cytotoxic than AZT except the retinoic acid ester. In vitro hydrolysis of the various esters in human plasma indicated that these agents were relatively stable toward plasma esterases with t1/2 ranging from 10 to 240 min. Drug uptake studies in H9 cells with radiolabeled analogues demonstrated that the retinoic acid ester achieved approximately 4-fold higher intracellular concentration than [3H]AZT. However, 1,4-dihydro-1-methyl-3-[(pyridylcarbonyl)oxy] ester (5) was the most active agent of this series and had a higher therapeutic index than AZT.

In a attempt to alleviate the drug-related toxicity of zidovudine in patients with AIDS, a pro-drug of zidovudine, 5′-{(1,4-dihydro-1-methyl-3-pyridinylcarbonyl)oxy}-3′-azido-2′,3′-dideoxythymidine (DP-AZT), has been evaluated. Cellular uptake by H9 cells and peripheral blood lymphocytes (PBL) with zidovudine and DP-AZT showed at least a 50% greater intracellular concentration of DP-AZT with-in 2 hr. DP-AZT was significantly less toxic to murine bone marrow cells as measured by CFU-E assay. The ED 50 concentration to inhibit the production of HIV specific p24 antigen was 0.05 μM for DP-AZT whereas zidovudine required 0.125 μM. These results demonstrated that DP-AZT has a higher therapeutic ratio than zidovudine as an anti-HIV-1 agent.

ω-(2,6-Dimethyl-4-pyrimidinylthio-(4), 2-methyl-4-quinazolinylthio-(9), and 4-oxo-2-quinazo-linylthio)-(10) acetophenones with hydrochloric or perchloric acid provide 2,5-diaryl-1,4-dithiins (7) whereas α)-(6-methyl-4-pyrimidinylthio) acetophenones (11) with aq HCl/HClO4, or POCl3 followed by hydrolysis provide 1-(4-aryl-2-thiazolyl)-2-propanones (12). Likewise, 2-(6-methyl-4-pyrimidinylthio) cyclohexanone (13) give the thiazole derivative (14).

Six new polysiloxane materials containing chiral amide side-chains have been prepared by the hydrosilylation of appropriate amide-containing alkenes onto polyhydromethylsiloxane. The alkenes were prepared from either 4-allyloxybenzoic acid or 4-vinylbenzoic acid and the following chiral amines: (S) -1-(1 -naphthyl)ethylamine, (R) -α-methylbenzylamine, the 4-methoxyphenyl ester of alanine and the isopropyl ester of isoleucine. The polysiloxane containing about 7% of the chiral amide prepared from (R) - N -(α-methylbenzyl)-4-allyloxybenzamide proved to be an efficient stationary phase for the capillary gas chromatographic separation of the enantiomers of the N -pentafluoropropionyl isopropyl esters of amino acids of which one example is given. This stationary phase was stable to 280°C.

The synthesis of 3H-labelled azidothymidine (AZT) from [methyl-3H]thymidine is described. Purification of labelled AZT was accomplished by column chromatography. The purity of the labelled compound was determined by high performance liquid chromatography connected with a radioactive flow detector. The labelled AZT was found to be stable at pH ranging from 2.3 to 7.4 at 37°C and at hyperthermic temperature of 42°C.

A series of new polysiloxanes containing chiral side groups has been prepared. These polymers were prepared by hydrosilylating chiral alkene derivatives onto polyhydromethylsiloxane. The alkene derivatives were prepared from (+) or (-)-2-phenyl-3-butenoic acid, (R)-1-hepten-3-ol and (R)-1-cyclohexyl-2-propen-1-ol. Polysiloxanes containing racemic substituents were also prepared fron derivatives of racemic 3-buten-2-ol. The polysiloxanes containing biphenyl carboxylate derivatives (11a–13a) had liquid crystalline properties. These polymers were prepared for use as stationary phases for capillary gas and supercritical fluid chromatography.

4-(4-Quinazolinylthio)-butan-2-one and 3-(4-quinazolinylthio) propiophenone (4, R = CH3, C6H5) with POCl3 give 3-(3-oxobutyl)-4(3 H )-quinazolone and 3-(2-benzoylethyl)-4(3H)-quinazolone (7, R = CH3, C6H5, X = O) via S → N rearrangement followed by conversion. Non-protic heterocyclic thioamides undergo similar oxidation.

Conversion d'arylimines de benzaldehyde, et d'isoquinoleine, quinoxaline et phtalazine en N-aryl benzamides et isoquinolone-1, quinoxalinedione-2,3 et phtalazinone-1 respectivement

With aq. sodium hydroxide, ω - (4(3 H )-quinazolinylidene) acetophenones , 4b (R'= H, R=Ar) or ω-(4-quinazolinyl) acetophenones 4a (R'= Me, Et; R = Ar) provide 4-alkylquinazolines 6 but 1-methyl-4-phenacyl or phenacylidene-3 H -quinazolinium derivatives 10a or 10b give N-methyl-4-quinolone derivatives 11 .

Synthese des composes du titre par reaction de [methyl-6 pyrimidinyl-4 thio]-2 acetophenones avec HCl/HClO 4 aqueux ou POCl 3 suivie d'hydrolyse